Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Gilead sales

    - PMLiVE

    Gilead agrees on affordable medicines plan with US government

    The company recently announced a $32bn investment in US R&D and manufacturing

    - PMLiVE

    Gilead’s Yescarta shows benefits for patients with large B-cell lymphoma

    This is the most common type of non-Hodgkin lymphoma worldwide

    - PMLiVE

    Gilead reports Trodelvy breast cancer trial missed primary survival endpoint

    The drug treatment is being evaluated in several ongoing phase 3 trials

    - PMLiVE

    Invivyd working with FDA towards potential Biologics License Application for COVID-19

    The company plans head-to-head safety evaluation with COVID-19 vaccine, pending regulatory alignment

    - PMLiVE

    FDA approves Pfizer and BioNTech’s jab for COVID-19

    Globally, five billion doses of the companies’ vaccine have been distributed

    - PMLiVE

    Moderna’s LP.8.1-adapted COVID-19 vaccine recommended by CHMP

    Global health authorities have recommended that vaccines for the 2025-2026 season should target LP.8.1

    - PMLiVE

    Gilead shares promising phase 3 results for Trodelvy plus Keytruda in aggressive breast cancer

    Triple-negative breast cancer accounts for approximately 15% of all cases of the disease

    - PMLiVE

    EC approves CSL/Arcturus’ self-amplifying mRNA COVID-19 vaccine Kostaive

    Kostaive is designed to instruct the body to make more mRNA to boost immune response

    - PMLiVE

    WHO urges US to ‘reconsider’ withdrawal from global health organisation

    President Donald Trump said the agency mishandled the COVID-19 pandemic and other global health crises

    - PMLiVE

    Gilead’s seladelpar recommended by CHMP to treat primary biliary cholangitis

    The rare liver disease affects approximately 15 per 100,000 people in Europe

    - PMLiVE

    Sanofi receives FDA fast track designation for COVID-19/flu combination vaccines

    The combined vaccine approach could simplify immunisation practices and lead to higher uptake

    - PMLiVE

    Merck and Ridgeback initiate phase 3 study of COVID-19 oral antiviral in high-risk adults

    Lagevrio is already available in the US under emergency use authorisation to treat certain cases of COVID-19

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links